Literature DB >> 19273081

Perspectives in PML: a unifying framework for PML function.

Katherine L B Borden1, Biljana Culjkovic.   

Abstract

The promyeloctyic leukemia protein (PML) has established activities as a potent repressor of proliferation, and oncogenic transformation, a promoter of apoptosis, an inducer of senescence, and may act as an inhibitor of angiogenesis in mammalian systems. Loss of PML or its nuclear bodies is associated with many human disease states. At the molecular level, the PML protein, and its associated nuclear bodies, play roles in diverse events ranging from mRNA export to DNA repair. PML expression impacts on Akt survival signaling, p53/Mdm2 activity, and cell cycle progression, to name a few. However, there is no discrete set of molecular activities associated with the PML protein that underlie its biochemical and physiological effects. In this review, we postulate a possible molecular model of PML function that could provide a unifying underpinning for many of its disparate activities. In particular, we explore how the ability of PML to coordinately and combinatorially regulate gene expression post-transcriptionally, enables PML to have such broad ranging effects on cellular physiology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273081     DOI: 10.2741/3258

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  11 in total

Review 1.  PML nuclear bodies.

Authors:  Valérie Lallemand-Breitenbach; Hugues de Thé
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

2.  Assembly dynamics of PML nuclear bodies in living cells.

Authors:  Peter Brand; Thorsten Lenser; Peter Hemmerich
Journal:  PMC Biophys       Date:  2010-03-05

3.  Adenovirus E4orf3 targets transcriptional intermediary factor 1γ for proteasome-dependent degradation during infection.

Authors:  Natalie A Forrester; Rakesh N Patel; Thomas Speiseder; Peter Groitl; Garry G Sedgwick; Neil J Shimwell; Robert I Seed; Pól Ó Catnaigh; Christopher J McCabe; Grant S Stewart; Thomas Dobner; Roger J A Grand; Ashley Martin; Andrew S Turnell
Journal:  J Virol       Date:  2011-12-28       Impact factor: 5.103

4.  Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein.

Authors:  Qingkai Yang; Xianming Deng; Bingwen Lu; Michael Cameron; Colleen Fearns; Matthew P Patricelli; John R Yates; Nathanael S Gray; Jiing-Dwan Lee
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

5.  The ND10 Component Promyelocytic Leukemia Protein Acts as an E3 Ligase for SUMOylation of the Major Immediate Early Protein IE1 of Human Cytomegalovirus.

Authors:  Nina Reuter; Eva-Maria Schilling; Myriam Scherer; Regina Müller; Thomas Stamminger
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

Review 6.  Tumor suppressive pathways in the control of neurogenesis.

Authors:  Stefano Bartesaghi; Paolo Salomoni
Journal:  Cell Mol Life Sci       Date:  2012-07-17       Impact factor: 9.261

7.  The human cytomegalovirus major immediate-early proteins as antagonists of intrinsic and innate antiviral host responses.

Authors:  Christina Paulus; Michael Nevels
Journal:  Viruses       Date:  2009-11-05       Impact factor: 5.048

8.  Cellular promyelocytic leukemia protein is an important dengue virus restriction factor.

Authors:  Federico Giovannoni; Elsa B Damonte; Cybele C García
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

Review 9.  Host cell factors as antiviral targets in arenavirus infection.

Authors:  Florencia N Linero; Claudia S Sepúlveda; Federico Giovannoni; Viviana Castilla; Cybele C García; Luis A Scolaro; Elsa B Damonte
Journal:  Viruses       Date:  2012-09-13       Impact factor: 5.048

10.  Promyelocytic leukemia (PML) protein plays important roles in regulating cell adhesion, morphology, proliferation and migration.

Authors:  Mei Kuen Tang; Yong Jia Liang; John Yeuk Hon Chan; Sing Wan Wong; Elve Chen; Yao Yao; Jingyi Gan; Lihai Xiao; Hin Cheung Leung; Hsiang Fu Kung; Hua Wang; Kenneth Ka Ho Lee
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.